226 related articles for article (PubMed ID: 31197461)
21. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.
Zhang YL; Li J; Mo HY; Qiu F; Zheng LM; Qian CN; Zeng YX
Mol Cancer; 2010 Jan; 9():4. PubMed ID: 20064222
[TBL] [Abstract][Full Text] [Related]
22. Expression of Cathepsin K in Skull Base Chordoma.
Tian K; Ma J; Wang L; Wang K; Li D; Hao S; Yang Y; Du J; Jia G; Zhang L; Wu Z; Zhang J
World Neurosurg; 2017 May; 101():396-404. PubMed ID: 28216213
[TBL] [Abstract][Full Text] [Related]
23. Effect comparisons among treatment measures on progression-free survival in patients with skull base chordomas: a retrospective study of 234 post-surgical cases.
Wang L; Tian K; Ma J; Wang K; Jia G; Wu Z; Zhang L; Zhang J
Acta Neurochir (Wien); 2017 Oct; 159(10):1803-1813. PubMed ID: 28699066
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.
Xia C; Huang W; Chen YL; Fu HB; Tang M; Zhang TL; Li J; Lv GH; Yan YG; Ouyang ZH; Yao N; Wang C; Zou MX
Front Immunol; 2021; 12():797407. PubMed ID: 35145510
[TBL] [Abstract][Full Text] [Related]
25. [Relationship Between Tim-3 and Galectin-9 Expression Levels, Clinical Pathological Characteristics, and Prognosis in Patients After Radical Resection of Colorectal Cancer].
Zhang Y; Deng D; Yin W; Luo J; Liu J; Xie C; Ji X; Ma L; Zhang L; Xia X; Cheng S; Huang A; Yang F
Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 55(2):375-382. PubMed ID: 38645842
[TBL] [Abstract][Full Text] [Related]
26. Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients.
Li X; Chen Y; Liu X; Zhang J; He X; Teng G; Yu D
Int Immunopharmacol; 2017 Mar; 44():153-159. PubMed ID: 28103502
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.
Bai J; Zhai Y; Wang S; Gao H; Du J; Wang J; Li M; Li C; Gui S; Zhang C; Sun Y; Zhang Y
World Neurosurg; 2017 Mar; 99():282-287. PubMed ID: 27916725
[TBL] [Abstract][Full Text] [Related]
28. Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma.
Zou MX; Huang W; Wang XB; Lv GH; Li J; Deng YW
Int J Clin Exp Pathol; 2014; 7(8):4877-85. PubMed ID: 25197358
[TBL] [Abstract][Full Text] [Related]
29. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
30. High Expression of TGF-β1 Predicting Tumor Progression in Skull Base Chordomas.
Ma J; Tian K; Wang L; Wang K; Du J; Li D; Wu Z; Zhang J
World Neurosurg; 2019 Nov; 131():e265-e270. PubMed ID: 31349076
[TBL] [Abstract][Full Text] [Related]
31. Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center.
Meng T; Yin H; Li B; Li Z; Xu W; Zhou W; Cheng M; Wang J; Zhou L; Yang X; Liu T; Yan W; Song D; Xiao J
Neuro Oncol; 2015 May; 17(5):725-32. PubMed ID: 25488908
[TBL] [Abstract][Full Text] [Related]
32. Factors predicting recurrence after resection of clival chordoma using variable surgical approaches and radiation modalities.
Jahangiri A; Chin AT; Wagner JR; Kunwar S; Ames C; Chou D; Barani I; Parsa AT; McDermott MW; Benet A; El-Sayed IH; Aghi MK
Neurosurgery; 2015 Feb; 76(2):179-85; discussion 185-6. PubMed ID: 25594191
[TBL] [Abstract][Full Text] [Related]
33. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis.
Bohman LE; Koch M; Bailey RL; Alonso-Basanta M; Lee JY
World Neurosurg; 2014 Nov; 82(5):806-14. PubMed ID: 25009165
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Factors and Survival Outcome in Patients with Chordoma in the United States: A Population-Based Analysis.
Lee IJ; Lee RJ; Fahim DK
World Neurosurg; 2017 Aug; 104():346-355. PubMed ID: 28457925
[TBL] [Abstract][Full Text] [Related]
35. Proposal and Validation of a Basic Progression Scoring System for Patients with Skull Base Chordoma.
Ma JP; Tian KB; Wang L; Wang K; Li D; Yang Y; Du J; Ru XJ; Zhang LW; Wu Z; Zhang JT
World Neurosurg; 2016 Jul; 91():409-18. PubMed ID: 27132181
[TBL] [Abstract][Full Text] [Related]
36. Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion.
Gao Z; Zhang Q; Kong F; Chen G; Li M; Guo H; Liang J; Bao Y; Ling F
Med Oncol; 2012 Dec; 29(4):2438-44. PubMed ID: 22351250
[TBL] [Abstract][Full Text] [Related]
37. MR Imaging Grading System for Skull Base Chordoma.
Tian K; Wang L; Ma J; Wang K; Li D; Du J; Jia G; Wu Z; Zhang J
AJNR Am J Neuroradiol; 2017 Jun; 38(6):1206-1211. PubMed ID: 28428207
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.
Longoni M; Orzan F; Stroppi M; Boari N; Mortini P; Riva P
Neuro Oncol; 2008 Feb; 10(1):52-60. PubMed ID: 18094369
[TBL] [Abstract][Full Text] [Related]
39. miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3.
Zhang H; Yang K; Ren T; Huang Y; Tang X; Guo W
Cell Death Dis; 2018 Jun; 9(6):680. PubMed ID: 29880900
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
